Mazdutide vs Survodutide

mazdutide vs survodutide is a close mechanism match but not a fair numbers race. Both are GLP-1/glucagon dual agonists with human randomized-trial evidence. Mazdutide is approved in China; survodutide remains in phase 3. No trial has compared them directly, so the honest choice depends on the goal, not a universal winner.

What is the core difference?

Mazdutide and survodutide press the same two receptor buttons, but regulatory geography and clinical emphasis separate them. Mazdutide has a China-centered phase 3 program and Chinese approvals for weight management and type 2 diabetes. Survodutide is Boehringer Ingelheim’s still-investigational candidate, with global obesity trials and a particularly deep liver-disease program.

Both compounds are a GLP-1 glucagon dual agonist. GLP-1 lowers food intake by reducing appetite, increasing fullness, and slowing stomach emptying. Glucagon is the extra lever: researchers are trying to add higher energy use and more direct liver-fat metabolism on top of appetite suppression. In a small human infusion experiment, GLP-1 plus glucagon reduced food intake and increased measured energy expenditure (PubMed).

That is what separates this class from semaglutide, which activates GLP-1 without a glucagon arm. The glucagon story is promising, but it should not be turned into a guaranteed “metabolic boost” for either drug. Human effects depend on dose, receptor balance, food intake, and trial context. Our plain-English guide to GIP vs GLP-1 shows where the other major dual-agonist strategy fits.

What do the human trials actually show?

Mazdutide and survodutide both caused meaningful weight loss in randomized phase 3 trials, which supports the shared human-rct badge. The studies compared each drug with placebo, not with one another. Reading separate percentages as a verdict on survodutide vs mazdutide would quietly invent a comparison the researchers never ran.

Mazdutide’s GLORY-2 trial enrolled 461 Chinese adults with moderate to severe obesity. A 9 mg weekly arm had a mean 16.65% weight reduction at week 60, versus 1.50% with placebo under the treatment-policy analysis. Vomiting, nausea, and diarrhea were the most common adverse events (JAMA).

Survodutide’s SYNCHRONIZE-1 trial enrolled 725 adults with obesity or overweight without diabetes. At week 76, mean weight change under the treatment-regimen analysis was 12.2% with 3.6 mg, 13.0% with 6.0 mg, and 5.4% with placebo. Gastrointestinal events were again the main problem (PubMed).

Can the trial percentages tell us which dual agonist is better?

The trial percentages cannot answer which dual agonist is better, because GLORY-2 and SYNCHRONIZE-1 differed in participants, countries, duration, dose escalation, placebo response, and statistical handling of treatment discontinuation. Putting 16.65% beside 13.0% is useful description. Calling the larger number a win is not evidence; it is spreadsheet theater.

The placebo groups alone show the trap. GLORY-2 reported 1.50% mean loss with placebo at 60 weeks, while SYNCHRONIZE-1 reported 5.4% at 76 weeks. Different background lifestyle programs and analysis rules can move the apparent drug-placebo gap before molecular differences enter the picture. A real winner claim needs a randomized mazdutide-versus-survodutide trial at appropriate doses. None exists.

Which compound fits which research goal?

Mazdutide fits the goal of regulatory maturity and established diabetes development; survodutide fits the goal of following a dedicated global MASH program. Neither earns a blanket efficacy crown. The by-goal cards below reflect program strength and approved status, not advice to obtain either compound or a claim that one person’s response is predictable.

Mazdutide is the clearer pick when the question is which compound has already satisfied a regulator. China’s NMPA approved mazdutide for chronic weight management in June 2025, based principally on the phase 3 GLORY-1 program (Innovent filing). China later approved glycemic control in adults with type 2 diabetes, matching the regulatory notes in our compound profile.

Survodutide is the clearer pick when the goal is tracking liver-specific development. In SYNCHRONIZE-MASLD, 68.5% of treated participants versus 28.6% on placebo achieved at least a 30% liver-fat reduction under the treatment-regimen analysis at 48 weeks. That trial supports the liver angle; the ongoing LIVERAGE studies are testing harder MASH and fibrosis outcomes (Nature Medicine).

For pure glucagon agonist weight loss, there is no defensible pick between the two yet. Both have positive placebo-controlled human evidence. Neither has proved superiority over the other.

How do dosing and side effects compare?

Mazdutide and survodutide are both studied as once-weekly injections under the skin, with gradual dose escalation used to manage stomach-related side effects. Mazdutide phase 3 programs include 4 mg, 6 mg, and 9 mg regimens; SYNCHRONIZE-1 titrated survodutide to 3.6 mg or 6.0 mg. Those milligram numbers are not dose equivalents.

Both trial programs report nausea, vomiting, diarrhea, constipation, or reduced appetite, with frequency changing by dose and titration. Cross-trial side-effect rankings have the same problem as cross-trial weight rankings: different populations and escalation schedules. Neither evidence base supports a home-mixed vial, and neither profile supplies a validated US consumer protocol.

What is the US regulatory and supply reality in 2026?

Neither compound is FDA-approved in 2026. Mazdutide’s Chinese approval does not authorize US sale, while survodutide remains an investigational phase 3 drug. FDA has already named products sold to Americans as “mazdutide” and “survodutide” in a warning letter, calling them unapproved new drugs with no approved applications in effect (FDA).

That makes the supply answer unusually clean: a US website selling either name is not offering an FDA-approved medicine or legitimate retail access to the developer’s trial product. A “research use only” label does not transform a consumer weight-loss drug into lawful supply. Our guide to grey-market peptides explains why identity, sterility, and dose claims remain unverified even when the vial looks professional.

The bottom line for mazdutide vs survodutide is therefore by goal: mazdutide for regulatory maturity in China and mature diabetes evidence; survodutide for the dedicated global MASH pipeline. For a US buyer, the practical answer is neither. For comparative efficacy, the evidence is still waiting on the trial that matters: a direct head-to-head.